Search for a report

GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2028

  • You are here:
  • Home
  • Downloads
  • GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2028

GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2028

The global irritable bowel syndrome treatment market is projected to register a CAGR of 7.25% and is anticipated to generate a revenue share of $1964.2 million by 2028. The base year considered for the market study is 2020, and the forecast years are 2021 to 2028. Irritable bowel syndrome (IBS) is a common disorder affecting the large intestine. It is also known as irritable colon, spastic colon, mucous colitis, and spastic colitis, and differs from inflammatory bowel disease. However, as a chronic condition, the patient has to manage the disease for a longer period.

GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2028

Global Irritable Bowel Syndrome Treatment Market by Type (Ibs With Diarrhea, Ibs With Constipation, Mixed Ibs) by Product (Rifaximin, Eluxadoline, Linaclotide, Lubiprostone, Other Products) by Distribution Channel (Drug Stores and Retail Pharmacies, Hospitals’ Pharmacies, Online Pharmacies) by Mechanism of Action (5ht3 Antagonist, Guanylate Cyclase Receptor-c Agonist, Chloride Channel Activator, Other Mechanism of Actions) by Dosage (Solid, Liquid) and by Geography

Request free sample

The global irritable bowel syndrome treatment market is projected to register a CAGR of 7.25% and is anticipated to generate a revenue share of $1964.2 million by 2028. The base year considered for the market study is 2020, and the forecast years are 2021 to 2028.

Irritable bowel syndrome (IBS) is a common disorder affecting the large intestine. It is also known as irritable colon, spastic colon, mucous colitis, and spastic colitis, and differs from inflammatory bowel disease. However, as a chronic condition, the patient has to manage the disease for a longer period.

To learn more about this report, request a free sample copy

Key factors propelling the global irritable bowel syndrome treatment market growth:

  • Rising incidence of gastrointestinal ailments
  • Growing number of drug developments and FDA approvals
  • Surging occurrence of irritable bowel syndrome
    • Health systems across regions are observing significant growth, in terms of the occurrence of irritable bowel syndrome.
    • This is mainly accredited to the lifestyle changes, which is projected to boost the market growth.
  • Increasing geriatric population

Major growth restraining factors:

  • High cost of drugs
  • Lack of skilled professionals
  • Limited treatment options
    • The market only has a few approved drugs for treating irritable bowel syndrome, when compared to the existing demand.
    • However, the drugs cater to a limited number of patients, since several medicines approved in specific regions are not available globally.

The report scope of the global irritable bowel syndrome treatment market includes the segmentation analysis of type, product, distributional channel, mechanism of action, and dosage. These segments are further classified to provide a detailed analysis of the studied market.

Market by Product:

  • Rifaximin
    • The rifaximin segment, under the product segment, is expected to record the highest CAGR.
    • Rifaximin’s mechanism of action is different from other antibiotics as it passes through the stomach and intestines without being absorbed into the bloodstream.
    • The product only treats intestinal tract infections and no other bodily infections.
  • Eluxadoline
  • Lubiprostone
  • Linaclotide
  • Other Products

Geographically, the global irritable bowel syndrome treatment market has been segmented based on four major regions, which includes:

  • North America: The United States and Canada
    • North America dominated the global market in 2020.
    • The region’s market growth is attributed to the factors such as the increasing incidence of irritable bowel syndrome and related conditions, as well as the growing numbers of FDA approvals and drug developments.
  • Europe: The United Kingdom, Germany, Italy, France, Belgium, Russia, Poland, and Rest of Europe
  • Asia Pacific: India, Australia & New Zealand, China, South Korea, Japan, Thailand, Indonesia, Vietnam, and Rest of Asia Pacific
    • The Asia Pacific is expected to lead the global market over the forecast period.
    • The rising focus of leading manufacturers on expanding their regional presence in developing countries is anticipated to drive the Asia Pacific’s market growth.
  • Rest of World: Latin America, the Middle East & Africa

Key market players operating in the global irritable bowel syndrome treatment market: 

  • Abbott laboratories
  • Allergan PLC
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Novartis AG
  • Others

Key strategies adopted by some of these companies:

In December 2020, Abbott announced that the United States Food and Drug Administration (FDA) approved the updated classification for Abbott’s HeartMate 3 heart pump for pediatric patients with progressive refractory left ventricular heart failure.

Key findings of the global irritable bowel syndrome treatment market:

  • The market observes several growth opportunities, especially across developing economies.
  • 5HT3 antagonist is the dominating mechanism of action.
  • The online pharmacies segment leads the distribution channel category.

 

Frequently Asked Questions (FAQs):

  • Why is the Asia Pacific anticipated to be the fastest-growing region?

A: The Asia Pacific is expected to be the fastest-growing region due to the increase in public awareness regarding irritable bowel syndrome, as well as the rising focus of drug makers in developing countries.

  • How do lifestyle changes propel the global irritable bowel syndrome market growth?

A: Due to the change in lifestyle, people suffering from irritable bowel syndrome are prone to psychological disorders and go through a stressful life. They also suffer from emotional troubles, thereby intensifying the impact of the condition, and driving the market growth.

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    •    KEY DRIVERS
      • RISE IN THE INCIDENCE OF GASTROINTESTINAL AILMENTS
      • GROWING NUMBER OF DRUG DEVELOPMENTS AND FDA APPROVALS
      • SURGING OCCURENCE OF IRRITABLE BOWEL SYNDROME
      • INCREASING GERIATRIC POPULATION
    •    KEY RESTRAINTS
      • HIGH COST OF DRUGS
      • LACK OF SKILLED PROFESSIONALS IN DEVELOPING ECONOMIES
      • LIMITED TREATMENT OPTIONS
  1. KEY ANALYTICS
    •    PORTER’S FIVE FORCES ANALYSIS
      • THREAT OF NEW ENTRY
      • THREAT OF SUBSTITUTION
      • BUYER’S POWER
      • SUPPLIER’S POWER
      • COMPETITIVE RIVALRY
    • IMPACT OF COVID-19 ON IRRITABLE BOWEL SYNDROME TREATMENT MARKET
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • KEY INVESTMENT INSIGHTS
  2. MARKET BY TYPE
    • IBS WITH DIARRHEA
    • IBS WITH CONSTIPATION
    • MIXED IBS
  3. MARKET BY PRODUCT
    • RIFAXIMIN
    • ELUXADOLINE
    • LINACLOTIDE
    • LUBIPROSTONE
    • OTHER PRODUCTS
  4. MARKET BY DISTRIBUTION CHANNEL
    • DRUG STORES AND RETAIL PHARMACIES
    • HOSPITALS’ PHARMACIES
    • ONLINE PHARMACIES
  5. MARKET BY MECHANISM OF ACTION
    • 5HT3 ANTAGONIST
    • GUANYLATE CYCLASE RECEPTOR-C AGONIST
    • CHLORIDE CHANNEL ACTIVATOR
    • OTHER MECHANISM OF ACTIONS
  6. MARKET BY DOSAGE
    • SOLID
    • LIQUID
  7. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      •    COUNTRY ANALYSIS
        • UNITED STATES
        • CANADA
    •     EUROPE
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      •    COUNTRY ANALYSIS
        • GERMANY
        • FRANCE
        • UNITED KINGDOM
        • ITALY
        • RUSSIA
        • BELGIUM
        • POLAND
        • REST OF EUROPE
    •     ASIA PACIFIC
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      •    COUNTRY ANALYSIS
        • JAPAN
        • CHINA
        • AUSTRALIA & NEW ZEALAND
        • INDIA
        • SOUTH KOREA
        • THAILAND
        • INDONESIA
        • VIETNAM
        • REST OF ASIA PACIFIC
    •     REST OF WORLD
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGE
      • KEY PLAYERS
      •    REGIONAL ANALYSIS
        • LATIN AMERICA
        • MIDDLE EAST & AFRICA
  1. COMPETITIVE LANDSCAPE
    •    KEY STRATEGIC DEVELOPMENTS
      • MERGER & ACQUISITIONS
      • PRODUCT LAUNCH & DEVELOPMENTS
      • PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
      • BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
    •    COMPANY PROFILE
      • ABBOTT LABORATORIES
      • BAUSCH HEALTH COMPANIES INC
      • ALLERGAN PLC
      • ARDELYX INC
      • ASTELLAS PHARMA INC
      • ASTRAZENECA PLC
      • GLAXOSMITHKLINE PLC
      • IRONWOOD PHARMACEUTICALS INC
      • JOHNSON & JOHNSON (MCNEIL CONSUMER HEALTHCARE)
      • LANNETT COMPANY INC
      • NOVARTIS AG
      • SEBELA PHARMACEUTICALS INC
      • SYNTHETIC BIOLOGICS INC
      • TAKEDA PHARMACEUTICAL COMPANY LTD

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – IRRITABLE BOWEL SYNDROME TREATMENT

TABLE 2: NUMBER OF PERSONS AGED 65 YEARS OR OVER BY GEOGRAPHIC REGION, 2019 AND 2050

TABLE 3: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 4: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 5: GLOBAL IBS WITH DIARRHEA MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 6: GLOBAL IBS WITH DIARRHEA MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 7: GLOBAL IBS WITH CONSTIPATION MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 8: GLOBAL IBS WITH CONSTIPATION MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 9: GLOBAL MIXED IBS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 10: GLOBAL MIXED IBS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 11: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 12: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 13: GLOBAL RIFAXIMIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 14: GLOBAL RIFAXIMIN MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 15: GLOBAL ELUXADOLINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 16: GLOBAL ELUXADOLINE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 17: GLOBAL LINACLOTIDE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 18: GLOBAL LINACLOTIDE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 19: GLOBAL LUBIPROSTONE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 20: GLOBAL LUBIPROSTONE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 21: GLOBAL OTHER PRODUCTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 22: GLOBAL OTHER PRODUCTS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 23: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 24: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 25: GLOBAL DRUG STORES AND RETAIL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 26: GLOBAL DRUG STORES AND RETAIL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 27: GLOBAL HOSPITALS’ PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 28: GLOBAL HOSPITALS’ PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 29: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 30: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 31: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 32: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 33: GLOBAL 5HT3 ANTAGONIST MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 34: GLOBAL 5HT3 ANTAGONIST MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 35: GLOBAL GUANYLATE CYCLASE RECEPTOR-C AGONIST MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 36: GLOBAL GUANYLATE CYCLASE RECEPTOR-C AGONIST MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 37: GLOBAL CHLORIDE CHANNEL ACTIVATOR MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 38: GLOBAL CHLORIDE CHANNEL ACTIVATOR MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 39: GLOBAL OTHER MECHANISM OF ACTIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 40: GLOBAL OTHER MECHANISM OF ACTIONS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 41: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 42: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 43: GLOBAL SOLID MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 44: GLOBAL SOLID MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 45: GLOBAL LIQUID MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 46: GLOBAL LIQUID MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 47: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 48: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 49: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 50: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 51: LEADING PLAYERS OPERATING IN NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET

TABLE 52: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 53: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 54: LEADING PLAYERS OPERATING IN EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET

TABLE 55: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 56: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 57: LEADING PLAYERS OPERATING IN ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET

TABLE 58: REST OF WORLD IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 59: REST OF WORLD IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 60: LEADING PLAYERS OPERATING IN REST OF WORLD IRRITABLE BOWEL SYNDROME TREATMENT MARKET

LIST OF FIGURES

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, IN 2020

FIGURE 6: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH DIARRHEA, 2021-2028 (IN $ MILLION)

FIGURE 7: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH CONSTIPATION, 2021-2028 (IN $ MILLION)

FIGURE 8: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MIXED IBS, 2021-2028 (IN $ MILLION)

FIGURE 9: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, IN 2020

FIGURE 10: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY RIFAXIMIN, 2021-2028 (IN $ MILLION)

FIGURE 11: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ELUXADOLINE, 2021-2028 (IN $ MILLION)

FIGURE 12: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LINACLOTIDE, 2021-2028 (IN $ MILLION)

FIGURE 13: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LUBIPROSTONE, 2021-2028 (IN $ MILLION)

FIGURE 14: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER PRODUCTS, 2021-2028 (IN $ MILLION)

FIGURE 15: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, IN 2020

FIGURE 16: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DRUG STORES AND RETAIL PHARMACIES, 2021-2028 (IN $ MILLION)

FIGURE 17: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY HOSPITALS’ PHARMACIES, 2021-2028 (IN $ MILLION)

FIGURE 18: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ONLINE PHARMACIES, 2021-2028 (IN $ MILLION)

FIGURE 19: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, IN 2020

FIGURE 20: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY 5HT3 ANTAGONIST, 2021-2028 (IN $ MILLION)

FIGURE 21: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY GUANYLATE CYCLASE RECEPTOR-C AGONIST, 2021-2028 (IN $ MILLION)

FIGURE 22: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY CHLORIDE CHANNEL ACTIVATOR, 2021-2028 (IN $ MILLION)

FIGURE 23: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER MECHANISM OF ACTIONS, 2021-2028 (IN $ MILLION)

FIGURE 24: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, IN 2020

FIGURE 25: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY SOLID, 2021-2028 (IN $ MILLION)

FIGURE 26: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LIQUID, 2021-2028 (IN $ MILLION)

FIGURE 27: NORTH AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 28: UNITED STATES IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 29: CANADA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 30: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 31: GERMANY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 32: FRANCE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 33: UNITED KINGDOM IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 34: ITALY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 35: RUSSIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 36: BELGIUM IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 37: POLAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 38: REST OF EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 39: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 40: JAPAN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 41: CHINA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 42: AUSTRALIA & NEW ZEALAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 43: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 44: SOUTH KOREA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 45: THAILAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 46: INDONESIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 47: VIETNAM IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 48: REST OF ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 49: REST OF WORLD IRRITABLE BOWEL SYNDROME TREATMENT MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)

FIGURE 50: LATIN AMERICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 51: MIDDLE EAST & AFRICA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

  1. MARKET BY TYPE
    • IBS WITH DIARRHEA
    • IBS WITH CONSTIPATION
    • MIXED IBS
  2. MARKET BY PRODUCT
    • RIFAXIMIN
    • ELUXADOLINE
    • LINACLOTIDE
    • LUBIPROSTONE
    • OTHER PRODUCTS
  3. MARKET BY DISTRIBUTION CHANNEL
    • DRUG STORES AND RETAIL PHARMACIES
    • HOSPITALS’ PHARMACIES
    • ONLINE PHARMACIES
  4. MARKET BY MECHANISM OF ACTION
    • 5HT3 ANTAGONIST
    • GUANYLATE CYCLASE RECEPTOR-C AGONIST
    • CHLORIDE CHANNEL ACTIVATOR
    • OTHER MECHANISM OF ACTIONS
  5. MARKET BY DOSAGE
    • SOLID
    • LIQUID
  6. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      •    COUNTRY ANALYSIS
        • UNITED STATES
        • CANADA
    •     EUROPE
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      •    COUNTRY ANALYSIS
        • GERMANY
        • FRANCE
        • UNITED KINGDOM
        • ITALY
        • RUSSIA
        • BELGIUM
        • POLAND
        • REST OF EUROPE
    •     ASIA PACIFIC
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      •    COUNTRY ANALYSIS
        • JAPAN
        • CHINA
        • AUSTRALIA & NEW ZEALAND
        • INDIA
        • SOUTH KOREA
        • THAILAND
        • INDONESIA
        • VIETNAM
        • REST OF ASIA PACIFIC
    •     REST OF WORLD
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGE
      • KEY PLAYERS
      •    REGIONAL ANALYSIS
        • LATIN AMERICA
        • MIDDLE EAST & AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    Choose License Type

    Buy Now